Study S002321

Efficacy and Safety of Once Weekly Semaglutide in Adults With Obesity and Inadequately Controlled Type 1 Diabetes Using Hybrid Closed-Loop System.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05537233
Acronym: ADJUST-T1D
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 115
Start: 2023-04-11
Primary completion: 2024-08-06
Lead sponsor: Viral N. Shah
Conditions: Type 1 Diabetes; Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group [26 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0045777	2866-LB: Semaglutide Use Along with Neural Network Fully Closed-Loop Systems Improves Time in Range (TIR) to 87% in Adults with Type 1 diabetes: In Silico Study Dayu Lv, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05537233
R0017153	Semaglutide in Adults with Type 1 Diabetes and Obesity. Shah VN, NEJM evidence	2025	Randomized trial	PMID 40550013 DOI	cites ClinicalTrials.gov:NCT05537233; registry reference DERIVED:40550013